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Abstract
This chapter aims at exploring the use and misuse of cannabinoids as it has become a
major societal issue. In the first section, we describe the historical use of cannabis as a
natural cure in ancient civilizations. We then explore the current use of cannabinoids in
medicine, which includes innovative strategies for treating various diseases such as
multiple sclerosis or cancer‐induced pain. In the second section, we consider how the
discovery  and  characterization  of  the  endocannabinoid  system  have  increased
knowledge of this system's mode of action. Consumption of cannabis for recreational
use however is a significant public health issue today. Scientific advances are confront‐
ed with the adverse health effects that are demonstrated in preclinical and clinical
studies based on the psychotic and addictive properties of this compound. In the third
section, we therefore provide an overview of the recent findings on the endocannabi‐
noid system using animal models with proposed molecular mechanisms and poten‐
tial interactions with other neuromodulatory systems like the opioid system. Finally,
through alternative strategies to current treatments with both phyto‐ and synthetic
cannabinoids, we try to reconcile the beneficial aspects of the use of cannabinoids for
medication and the aspects associated with addictive properties.
Keywords: animal models, cannabis, dependence, endocannabinoid, pharmacology,
therapies
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1. Cannabis as medication
1.1. Historical uses of cannabis
Cannabis is a botanical genus belonging to annual plants from the Cannabaceae family.
According to botanical classification, this genus only contains one species Cannabis sativa L.
subdivided into three subtypes: sativa, indica, and ruderalis. Cannabis sativa was one of the first
plants cultivated by humans. In the 4th millenary BC in China, cannabis was mainly pro‐
duced for its stalk fibers, which were used to manufacture strings, ropes, textiles, and paper.
It was also consumed for its fruits [1]. Cannabis has been used as a natural medication for
thousands of years. It can be traced back to 2700 BC, but at that time it was only transmitted
by oral traditions [1]. The first written evidence of its therapeutic use was reported during the
first century of the Christian era, with the world's oldest pharmacopoeia, the Chinese
Pharmacopoeia Shen Nong Ben Cao Jing [2]. The main uses of cannabis were for treatment of
rheumatic pain, constipation, disorders of the female reproductive system, and also malaria.
In India, its use was mostly for analgesic, anticonvulsivant, tranquilizer, antispasmodic,
digestive, appetite stimulant, or antitussive properties. Cannabis also spread throughout Asia
for use in religious rituals as it was described as a magic and medicinal plant in the Atharva
Veda (4th Veda) sacred text of Hindu and Vedic traditions [1].
As cannabis has been prohibited by law, it has been difficult to follow its use for its recrea‐
tional properties. It has probably been used for recreational purpose since the beginning of the
Christian era. Additionally, its consumption for its psychoactive effects became quite popu‐
lar in the 1950s in the United States of America with the rise of jazz. It then spread among
young people within Western countries with, for example, the explosion of its popularity in
the 1960s–1970s with the hippie movement. Nowadays, cannabis and related compounds are
the most abused illicit substances in Europe, the United States, and Australia [3–5]. Consump‐
tion of cannabis is still often underestimated in our modern societies, but the current preva‐
lence has been estimated by the World Health Organization as about 3.9% among the global
population (15–64 years old) [6].
1.2. Phytocannabinoids
Today in the common language, the terms “cannabis” or “marijuana” stand for mixtures of
dried herbs (also named Bhang). In particular, the dried flowering tops, leaves, and stalks of
the mature female plant (Ganja) are commonly used as cannabis herbs [2]. Resinous extracts
of compressed flowering tops called “hashish” or “hash” are also consumed and are stron‐
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ger than marijuana [7]. Interestingly, the plant Cannabis sativa contains more than 400 different
chemical compounds including over 60 cannabinoids which are specific to the plants of the
genus Cannabis. These molecules are called phytocannabinoids. The most potent one is the (−)‐
Δ9‐tetrahydrocannabinol (Δ9‐THC) and has been purified and isolated in 1964 by Raphael
Mechoulam's team [8]. This molecule is the main psychoactive component of Cannabis sativa
and is therefore responsible for most of the psychoactive and physical effects of cannabis
consumption [9]. It has been described as a partial agonist for both cannabinoid receptors, CB1
and CB2 (see below) [10]. The other main active constituents of cannabis are the (−)‐Δ8‐
tetrahydrocannabinol (Δ8‐THC), the cannabinol (CBN), and the cannabidiol (CBD) [11]. The
Δ8‐THC is slightly less potent than Δ9‐THC, as CBN, and is present in very small quantities in
the plant. CBD is devoid of psychoactive effects and of most of the other Δ9‐THC‐like effects,
but has other interesting features such as antiepileptic, antianxiety, antinausea, and antischi‐
zophrenic properties [12]. Phytocannabinoids other than Δ9‐THC can show additive, syner‐
gistic, or antagonist effects with Δ9‐THC and these interactions may modulate its actions when
cannabis is consumed as an herbal mixture [13]. Noteworthy, Δ9‐THC content may strongly
vary upon the origin of the plants and the type of cannabis preparations. Since Δ9‐THC is the
main active compound of cannabis, refined farming methods and plant genetic crossbreed‐
ing technologies have been developed in order to increase Δ9‐THC content and therefore to
increase the potency of cannabis [13]. Depending on their relative content of Δ9‐THC and CBD,
cannabis plants are classified in three different types: “drug‐type” plants (Δ9‐THC/CBD > 1),
“intermediate‐type” plants (Δ9‐THC/CBD = 1), and “fiber‐type” plants (Δ9‐THC/CBD < 1) [14].
In addition to the relative content in various phytocannabinoids, consumption patterns also
impact the effects of cannabis.
1.3. Modes of cannabis consumption
Although cannabis is often mixed with tobacco, then rolled and smoked as “joints,” it can also
be consumed in other forms [13]. It can be smoked from pipe or even from “buckets” by
inhaling from a mass of plant or resin ignited in a plastic bottle. Moreover, it is ingested in the
form of candies or baked into cakes (cookies, muffins). In the latter case, cannabis is mixed
with butter to form “marijuana butter,” also called “cannabutter” or “Marrakech butter,” and
then mixed with other baking ingredients (“space cake”). Finally, more rarely, macerated
extracts of cannabis can be taken. Contrary to other drugs of abuse that can also be injected,
cannabis is unsuitable for intravenous use due to its relative insolubility in water. When
cannabis is taken as joints, the association of the phytocannabinoids with nicotine will produce
the hedonic effects sought by the smokers. It is therefore more difficult to study these effects
and the specific properties coming from cannabis alone. There are many factors influencing
the global effect of cannabis in humans resulting from combination of the relative content in
different phytocannabinoids (e.g., Δ9‐THC, CBD), the route of administration, the mode of
consumption (concomitant intake of nicotine, polyconsumption), the previous experiences of
the consumer with drugs, and the intake conditions [15]. Unlike other drugs of abuse such as
heroin, cocaine, or benzodiazepines, the risk of overdose of cannabis is rather low and no
sudden deaths directly linked to cannabis herbs have been reported so far [13].
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1.4. Psychological and systemic effects of cannabis
People primarily use cannabis for its positive effect on mood. Indeed, it results in an eupho‐
ria or “high,” characterized by a sensation of relaxation, decreased anxiety, awareness,
depression, and increased sociability depending on the intake conditions [16]. Nevertheless,
paradoxical reactions with dysphoria, anxiety, severe panic, and psychosis can be observed
when high doses of Δ9‐THC are taken. In some cases, similar effects can also occur at the first
consumption or for more psychologically vulnerable people [16]. Therefore, psychotropic
effects of cannabis are dose‐dependent and variable depending on the quantity of cannabis
consumed and on its Δ9‐THC content.
Cannabis use induces some adverse effects. It impairs cognitive and psychomotor function‐
ing [17]. Its consumption induces slowed reaction time, motor incoordination, short‐term
memory loss, as well as attention disorders, and so it thus disturbs driving capacities,
explaining the observed link between cannabis consumption and road accidents [13].
Furthermore, chronic use of cannabis may lead to long‐term effects on attention and memo‐
ry and these disturbances may last weeks or even several months after stopping cannabis
consumption [18]. Moreover, cannabis can increase the risk of psychotic symptoms. It has been
shown to induce the emergence of chronic psychosis such as schizophrenia in young consum‐
ers [19–21]. Finally, high and frequent cannabis consumption can lead to dependence and
therefore to development of tolerance and withdrawal syndromes (see below).
At the systemic level, cannabis has mainly cardiorespiratory effects [18]. Its impact on the
cardiovascular system can be reflected by induction of dose‐dependent tachycardia, vasodi‐
latation, and reddening of the ocular conjunctiva, the latter being a typical sign of cannabis
consumption. Postural hypotension and fainting can also be observed. Moreover, relation‐
ships between cannabis consumption and cardiac arrhythmias, cardiovascular ischemias,
coronary insufficiency, and other cases of fatal cardiac accidents have been reported [2, 22, 23].
Abusive cannabis consumption can indeed induce atrial [23] or ventricular fibrillations [24] in
predisposed patients and therefore represents a major risk for persons suffering from
preexisting cardiac diseases. It is noteworthy that young cannabis consumers are also at risk
in terms of cardiac consequences [25, 26].
Cannabis also has a strong impact on the respiratory system. The smoke of cannabis joints
contains the same constituents as tobacco (nicotine, noxious mixtures of gases and particu‐
lates) and smoking cannabis chronically causes coughing, bronchitis, and emphysema. Even
if the daily number of smoked cannabis joints is generally much lower than smoked conven‐
tional cigarettes, the differing manners in which cannabis is smoked may enhance the
deposition of smoke particulates at the pulmonary level in cannabis smokers, and therefore
explains specific respiratory consequences of cannabis [27]. It has been suggested that by
increasing oxidative stress and inducing mitochondrial dysfunctions [27] Δ9‐THC may
participate, in the long‐term, to the development of chronic airway diseases, pulmonary
infections, and even lung cancer in heavy smokers [13, 28, 29]. More attention should be given
to these adverse respiratory effects as habitual smoking of cannabis has greatly increased in
our modern society.
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Among other adverse effects of cannabis use, immunosuppressive and endocrine properties
have also been described as disturbing reproductive functions and fertility [18]. Depending
on the individual, cannabis can also induce a reduction in salivary secretion (sensation of dry
mouth) and an increase in appetite [30].
1.5. Current uses of medicinal cannabis
Medicinal or therapeutic cannabis refers to preparations using Cannabis sativa for a pure
medicinal purpose. Intake of these phytocannabinoids can include smoking, inhaling, local
application, or ingestion. Depending on the country, medicinal cannabis use is not allowed,
permitted, or accepted. In France, any use of cannabis was removed from the French
Pharmacopoeia in 1953 [31]. Its use, importation, sale, transportation, and production are
strictly forbidden. On the other hand, medicinal cannabis use is authorized in several countries,
including Canada, New‐Zealand, Australia, Netherlands, Spain, United Kingdom, and more
than 20 states in the United States of America. In Canada, for example, production and sale is
allowed under the supervision of Health Canada [32]. In the United States of America,
therapeutic cannabis is still classified as a “schedule I controlled substance” [33]. The American
Medical Association recently proposed rescheduling it to become a “Schedule II controlled
substance,” meaning that it has potential abuse risk and is accepted for therapeutic use [34].
Some states have voted on an amendment to permit medicinal use in conditions under
physician agreement for specific indications such as severe pain, cancer, cachexy, glaucoma,
AIDS, multiple sclerosis (MS), severe nausea, or sleep disorders [33–37]. This creates a
patchwork of state laws in the United States of America for legal use of medicinal cannabis,
its indications and maximal amount tolerated.
International
nonproprietary
name
Brand name Active ingredient(s) Indications
Dronabinol Marinol® Δ9‐THC Chemotherapy‐induced nausea and vomiting
AIDS‐related loss of appetite and weight loss
Nabilone Cesamet® Synthetic analogue of
Δ9‐THC
Chemotherapy‐induced nausea and vomiting
Nabiximols Sativex® Δ9‐THC and CBD
(ratio 1:1)
MS‐related spasticity
Table 1. Marketed cannabinoid‐based medicines.
Phytocannabinoids or derived compounds already exist on the market for some medicinal
interventions (Table 1). Δ9‐THC is mostly used as a therapeutic compound for its antiemetic
and orexigenic properties. It has been commercialized under Dronabinol (Marinol®) to
suppress nausea produced by chemotherapy and anorexia symptoms associated with AIDS.
A synthetic analogue of Δ9‐THC, Nabilone (Cesamet®), has also been produced to treat nausea
and vomiting linked to chemotherapy. Nabiximols (Sativex®) contains an equal mixture of the
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phytocannabinoids Δ9‐THC and CBD and is usually prescribed to relieve pain in adult patients
with MS or advanced cancer. It is administrated as a buccal spray in several countries,
including Canada, Spain, Denmark, Germany, and United Kingdom [38]. Interestingly, these
compounds are reported to only be used for recreational purposes and are therefore abused
extremely rarely [39]. Indeed, the mode of consumption (oral) and their pharmacokinetic
features delays a potential high effect for several hours and is therefore much less euphoric
than cannabis. Recently, Sativex has been suggested as a potential substitutive medication for
cannabis dependence and may help decrease withdrawal syndromes [40]. Table 2 summariz‐
es the current pathologies or symptoms treated with the approved phytocannabinoids
derivatives.
Pathologies Symptoms of the pathologies targeted by the
cannabinoids
References
Acquired immune deficiency syndrome
(AIDS)
Anorexia (loss of appetite and weight loss related) [38]
Cancers and chemotherapies Nausea and vomiting [38]
Neuropathic/chronic/inflammatory pain Pain intensity, inflammation, spasticity [35, 39, 42, 48]
Gilles de la Tourette syndrome Motor and verbal tics [43, 44]
Multiple sclerosis (MS) Spasticity [36, 45]
Amyotrophic lateral sclerosis (ALS) Tremors, motor deficiencies [234, 235]
Huntington's chorea Motor and cognitive disorders [232]
Psychosis and schizophrenia Anxiety, hallucinations, paranoia [219, 220]
Depression Sadness, demotivation, loss of interest, sleep disorders [255, 257]
Heroin addiction Craving [221]
Cannabis addiction Withdrawal syndrome [189, 268]
Cocaine addiction Hyperlocomotion, rewarding effects of cocaine [66, 127]
Osteoporosis Osteoclastogenesis, bone resorption, and bone fragility [236]
Table 2. Pathologies and associated symptoms targeted by cannabinoids.
For example, clinical studies have investigated the analgesic properties of medicinal canna‐
bis [35]. A comparison of cannabis's analgesic effect was performed between patients smok‐
ing cannabis and a placebo. A significant improvement in various types of pain including
chronic, postoperative or neuropathic pain, as well as pain in patients suffering of AIDS was
obtained [35]. A randomized clinical assay was conducted on patients with neuropathic pain
who smoked high or low concentrated cannabis (Δ9‐THC) or a placebo. This study showed
that cannabis is effective at ameliorating neuropathic pain [41]. Similar results were ob‐
tained in another randomized study including adults with AIDS‐associated sensory neuropa‐
thy where the effect of smoking low concentrated cannabis three times per day over 5 days
was compared with a placebo [42]. Other studies have suggested a potential role of smoking
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cannabis to alleviate some symptoms of Tourette's syndrome, a central nervous system (CNS)
disorder characterized by motor or verbal tics [43, 44]. Also, orally administered cannabis (a
mixture of Δ9‐THC and CBD) has been tested in cohorts of patients with MS and lower spasm
frequency and increase mobility has been observed [45]. Symptoms in patients who have MS
with muscle spasticity were treated with oral Δ9‐THC, cannabis extract, or placebo, and results
have shown that the first compound is more efficient in alleviating some aspects of the
disability [46]. These observations confirm the therapeutic interests of oral administration of
drugs containing Δ9‐THC such as Marinol® or Cesamet®.
1.6. Adverse effects of medicinal cannabis
It has been observed that the more Δ9‐THC content in medicinal cannabis, the more efficient
it is in alleviating pain [47]. But with high dose formulations, secondary effects such as
headache, dizziness, sleepiness, dry mouth or eye sensation, sedative effects, hypotension, and
impairments in memory and cognition can be observed by some patients [35, 47]. Also, the
best equilibrium to have an analgesic effect with the minimum side effects is strongly
dependent on the individual and the preparation of the drug (various content of phytocanna‐
binoids), which renders the dosage regimen particularly difficult. Indeed, in certain cases it
has also been shown that the benefit/risk ratio is not positive for chronic pain treatment as
cannabis only moderately reduce pain [48]. Recently, dronabinol has been tested for treat‐
ment of opiate withdrawal in a clinical trial and some adverse effects, including increased heart
rate, were observed at the examined dose [49]. These observations raise some concerns globally
about the dosage of such compound for potential benefits. Besides these potential adverse
effects, poor knowledge about the interaction of medicinal cannabis with other drugs and
possible psychotic and cognitive effects on patients are high safety concerns. Altogether, these
observations still limit current cannabis therapeutic use [35, 37].
It is noteworthy that current therapeutic use is directed to alleviate several symptoms of
various pathologies rather than being a cure for the patient. Cannabis plants containing high
level of CBD are associated with lower adverse effects [50] and therefore represent a major
therapeutic line of research for further drug design together with some synthetic derivatives
of cannabis (see below).
2. The endogenous cannabinoid system
In recent decades, the discovery and characterization of the endogenous cannabinoid system
represents a great milestone for research in the field, with considerable efforts being given to
create a better understanding of the mode of action of cannabinoids. The endocannabinoid
system comprises two well‐characterized receptors, cannabinoid receptors CB1 and CB2, and
their lipid neuromodulators (endocannabinoids), enzymes for their synthesis and their
degradation.
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2.1. Cannabinoid receptors
Cannabinoid receptors are receptors that were discovered in the early 1990s with CB1 and CB2
cloned from rat brain in 1990 and rat spleen in 1993, respectively [51–53]. They both are
membrane receptors coupled to G‐protein (Gαi/o) (GPCR) and share common signaling
properties (see below). They both bind Δ9‐THC, the main component of cannabis [54, 55].
CB1 and CB2 receptors share 48% peptidic sequence homology [10]. Radioligand binding
studies revealed a rather different distribution of these two receptors [56]. CB1 receptors are
mainly expressed in peripheral and central nervous systems as well as in the reproductive and
neuroendocrine systems [55, 57]. This receptor is highly abundant in the brain in areas involved
in memory and cognitive functions like the hippocampus, involved in reward processes such
as the striatum, ventral tegmental area, and prefrontal cortex, as well as in motor coordina‐
tion and psychomotor performances such as the cerebellum [58–62]. CB1 is also present in
brain structures involved in the regulation of appetite and nociception. With this wide pattern
of expression, CB1 receptors are therefore involved in various physiological functions and are
responsible for most of the psychoactive and central effects of cannabis.
CB2 receptors are highly expressed in the immune system in spleen, tonsil, thymus, masto‐
cytes, and blood cells. It has also been described in microglial cells [53, 55]. Several studies
have reported significant mRNA expression of CB2 receptors in brain areas such as granular
cells of the cerebellum [63, 64] in brain stem [65] as well as in dopaminergic neurons of the
VTA [66] and in a subset of excitatory and inhibitory neurons in CA1, CA3, and dentate gyrus
of the hippocampus [67]. Detection of CB2 proteins in brain structures is still controversial
because of the low expression and/or low specificity of available antibodies. Very little data
are available on the CB2 receptor's central function and a very recent study using a reporter
mouse line may help better clarifying the potential role of this receptor in brain functions [68].
The authors generated BAC transgenic GFP reporter mice to trace CB2 expression and could
detect, using fluorescence techniques, that the major sources for GFP‐CB2 expression are in B‐
cells in the spleen, blood, and microglia in the brain.
Pharmacological studies have proposed that other non‐CB1 and non‐CB2 receptors interact
with endocannabinoids such as channel vanilloid TRPV1 recognizing capsaicin [69] or the
orphan GPCR GPR55 [70, 71]. These receptors are not yet classified among cannabinoid
receptors, but interactions with cannabis could potentially explain some pharmacological
effects of this drug that cannot be accounted for by CB1 and CB2 activation [72].
2.2. Endocannabinoid synthesis and degradation
Two main endogenous ligands were discovered in the early 1990s: N‐arachidonoylethalona‐
mine or anandamide (AEA) which was isolated from pig brain [51] and 2‐arachidonoylgly‐
cerol (2‐AG) which was isolated from rat brain and dog intestine [73, 74]. Other
endocannabinoids have been identified, such as the N‐arachidonoyl‐dopamine (NADA), the
O‐arachidonoyl‐ethanolamine (virhodamine), or the 2‐arachidonoyl‐glycerylether (2‐AGE or
noladin), but their specific physiologic role needs further clarification [72].The 2‐AG is a full
agonist at both CB1 and CB2 receptors, whereas AEA is a partial agonist [75]. Interestingly, it
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has recently been shown that 2‐AG can be self‐administered by rats and can stimulate
dopamine (DA) transmission [76]. AEA also acts at TRPV1 receptors [11]. Both ligands show
no strong selectivity for CB1 and CB2, with a ratio generally below 10 [73, 77, 78]. Endoge‐
nous cannabinoids are lipid neuromodulators synthesized from distinct phospholipid
precursors. Several pathways have been described for their biosynthesis, noticeably for AEA
(for a recent review, see [79]). The N‐arachidonoyl phosphatidylethanolamine (NAPE) is one
precursor for AEA, which can be generated through a two‐step process involving a calcium‐
dependent transacylase and phospholipase D (NAPE‐PLD) [80]. 2‐AG synthesis mainly
involves phospholipase C and diacylglycerol lipases (DAGL) [74, 81, 82]. It has recently been
demonstrated using genetically modified mice that the DAGLα enzyme is directly responsi‐
ble for 2‐AG synthesis in the CNS [83]. Interestingly, 2‐AG participates in the synthesis of
arachidonic acid used for prostaglandin synthesis.
Postsynaptic neurons release endocannabinoid lipids. They cross the membrane by passive
diffusion or using still not well characterized transporter systems, and then mainly act on
presynaptic cannabinoid receptors. They are therefore retrograde synaptic messengers which
regulate synaptic transmission. The decrease of neurotransmitter release will occur both at
excitatory (glutamate) and inhibitory (gamma‐aminobutyric acid or GABA) synapses
(recently reviewed in [79, 84]). Endocannabinoids’ local action is fast, as they are rapidly
degraded through a recapture step through transporters, followed by enzymatic degrada‐
tion with the fatty acid amide hydrolase (FAAH) for AEA [85, 86] and the monoacylglycerol
lipase (MAGL) for 2‐AG [87].
2.3. Signaling pathways
Several signaling pathways are activated by cannabinoid receptors and have been extensive‐
ly reviewed [54, 55, 88]. Agonist activation induces inhibition of adenylate cyclase and a
reduction of intracellular AMPc levels and therefore a decrease of protein kinase A activity
[89]. On the other hand, beta and gamma subunits inhibit calcium voltage‐gated channels and
activate the opening of potassium channels. This effect results in membrane hyperpolariza‐
tion and a reduction in neurons excitability and therefore a decrease in neurotransmitter
release. At the presynaptic level this effect decreases the release of glutamate and GABA as
well as acetylcholine, noradrenaline, cholecystokinin, or corticotrophin [10]. Activation of
cannabinoid receptors also activates intracellular effectors stimulating MAPKinase signaling.
This regulation induces phosphorylation of transcription factors and leads to gene expres‐
sion modulation. CB1 signaling is well characterized and additional pathways have been
described, including activation by CB1 receptors of sphingolipid metabolism by either direct
synthesis of ceramide by serine‐palmitoyltransferases or hydrolysis of sphingomyelin [90]. In
astrocytes and glial cells, CB1 receptors are coupled to sphingomyelinase enzymes by
chaperone molecules to produce ceramide that participate to apoptotic signaling [91, 92]. On
the other hand, CB2 activation modulates a similar range of signaling pathways as the CB1
receptor, but clearly adenylate cyclase and MAPK pathways have been the most studied in
regard to selective CB2 agonists (recently reviewed in [93]).
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2.4. Physiological roles of the endocannabinoids
Endocannabinoids, by regulating the release of many neurotransmitters, act on various
biological processes in the nervous, digestive, reproductive, pulmonary, and immune systems.
Therefore, this system plays a critical role in a wide range of physiological functions, includ‐
ing energy balance, nociception and modulation of pain responses, and cognition and emotion
as well as in reward. The central and peripheral roles of the endocannabinoid system have
recently been extensively reviewed (see [94–101]) and the physiology and pathophysiology of
this system have been largely studied using classical pharmacology and genetically modi‐
fied animals [102]. Here, we provide just a few important specific points to illustrate these
many roles.
The endocannabinoid system participates in several perception processes. Among them,
nociception and modulation of pain responses have been particularly well studied and
stimulation of the endocannabinoid system globally decreases pain sensitivity [98, 103]. CB1
receptors are a central player in these responses, but CB2 receptors also play a crucial role in
the modulation of the immune response of the nervous system during neuropathic or joint
pain [104, 105]. The endocannabinoid system has been shown to participate in different types
of pain including acute, inflammatory, and neuropathic pain. Endocannabinoids like AEA also
have strong antinociceptive properties [106] and can decrease pain perception in a situation
of chemical skin damage, for example [107]. In terms of perception, this system also plays a
role in retina physiology [108]. CB1 receptors have been shown to be expressed in the inner
and outer plexiform layers of the retina of several species. Its activation in retinal bipolar cells
decreases the amplitude of voltage‐gated L‐type calcium channel currents and therefore
modulates photoreceptor activity. Also, CB2 expression has been demonstrated at RNA [109]
and protein [110] levels and a specific role for this receptor in shaping retinal responses to light
has been proposed [111]. These observations illustrate a modulatory role for the endocanna‐
binoid system in visual processing. Agonists for these receptors significantly decrease
intraocular pressure indicating a potential therapeutic effect for glaucoma treatment [112].
Noticeably, energy balance is an essential basic function where the endocannabinoid system
has been revealed to play a major role. Indeed, cannabis is well known for hunger activation
and specifically stimulating an appetite for sweet. Orexigenic properties of Δ9‐THC have been
confirmed on rat studies [113] and food intake is increased by CB1 receptor activation in
hypothalamic structures of the brain [114]. The endocannabinoid system is therefore clearly
involved, mainly through central CB1 receptor activation, in food intake behaviors and energy
balance [114–116]. It also plays a role in these processes by directly acting on peripheral organs
like the gastrointestinal tract where both CB1 and CB2 receptors are expressed and partici‐
pate in the regulation of motility and barrier function [117].
In the periphery, cannabinoid receptors are also expressed in cardiovascular tissues and their
endogenous ligands have distinct effects. For example, it has been shown that AEA and 2‐AG
induce vasodilation which can trigger hypotension [118]. They can also induce depressor
effects and bradycardia [119]. The endocannabinoid system clearly plays a role in cardiovas‐
cular‐related diseases and opposing effects of activation of CB1 and CB2 have been suggest‐
ed, highlighting potential therapeutic intervention [117].
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In the brain, CB1 receptors are highly expressed throughout many structures including the
hippocampus, cerebellum, and prefrontal cortex, suggesting a crucial role in cognitive
functions such as learning and memory, motor coordination, and emotions like anxiety or
depression and reward. Cannabis has been initially consumed to modify one's mood state and
CB1 is proposed as a strong contributor for this effect. A rodent model for depressive‐like
behaviors has recently been proposed with genetically modified animals where this receptor
is absent [120]. Dysfunction of many other processes is also produced by cannabis consump‐
tion and these events are thought to be mainly mediated through CB1 receptors. Interesting‐
ly, a possible implication in psychiatric disorders has been more recently proposed for CB2
receptors. A link between CB2 activation and schizophrenia has been considered [121, 122]. In
addition, recent evidence suggests a neuromodulator role of CB2 receptors in addictive
processes, with an implication in cocaine, nicotine, or ethanol effects [122–127]. Whether these
central effects are due to CB2 expression in neurons, microglia, or inflammatory cells is still
under investigation (see in [79]).
The endocannabinoid system also plays a neuroprotective role in some pathological condi‐
tions as it has been shown that CB1 receptors expressed specifically in glutamatergic hippo‐
campal neurons are both necessary and sufficient to provide substantial endogenous
protection against kainic‐acid‐induced seizures [128]. This system also modulates adult
neurogenesis in the hippocampus with a pivotal role in some steps of this process, probably
through activation of both CB1 and CB2 receptors (reviewed in [129].
Altogether pharmacological studies and preclinical models have allowed substantial prog‐
ress in understanding the cellular and molecular mechanisms of the prolonged use of
cannabinoids [130, 131]. In particular, genetically modified animal models, using knockout
and conditional knockout methodologies together with viral approaches (inactivation or re‐
expression of components of the endocannabinoid system), have greatly improved our
knowledge on the physiological and pathophysiological relevance of endocannabinoid
signaling (see [102]). The use of animal models is also greatly evolving with rapid genome
engineering technologies being developed using CRISPR‐Cas9 and will surely improve our
knowledge of the cannabinoid system [132, 133].
In conclusion, endocannabinoids are neuromodulators of important homeostatic mecha‐
nisms, including nociception and control of pain, vision, digestive and reproductive systems,
energy balance, mood regulation, cognitive functions, and immune system and reward
processing. Dysfunction of the system may induce pathologies and we particularly explore
the role of this system in the development of addiction.
3. Cannabis misuse and dependence
3.1. Cannabis misuse
Besides its medicinal use, cannabis has been used for its psychotropic effects and the addic‐
tive potential of its components, including Δ9‐THC, has been well described since the discov‐
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ery of the endogenous system. Indeed, cannabis and its derivatives represent the most
consumed illicit drug in modern countries worldwide. More popular than cocaine, ampheta‐
mines, ecstasy, or opiate in Europe, about 21.7% of citizens (15–64 years old) have taken
cannabis at least once in their life. This represents an estimated 14 million Europeans aged 15–
34 using the drug in the last year and about 3 millions using it daily. Among intensive cannabis
users, close to 7% of individuals have become dependent [134] and are now seeking treat‐
ment for cannabis‐induced disorders. Even if this represents a minority of consumers, it
globally represents a large number of people that may develop a cannabis‐related health
problem and is therefore a growing recognized public health threat [4]. Prevalence among
young people is greater and corresponds to recreational use. Moreover, it has been reported
that more men use cannabis, which may correspond to increased risk‐taking behavior, but one
cannot exclude a further increase of this behavior toward cannabis in women, as it has been
observed for other drugs of abuse such as tobacco or alcohol in recent years. Also, global intake
of cannabis is rather stable in Europe (Norway, Germany, France, and United Kingdom).
Nevertheless, some European countries where prevalence used to be low now show a
noticeable increase in cannabis use (Italy and Bulgaria). Internationally, cannabis use is still
controversial, as a strong disparity for its use and legal state is observed [4]. In the United States
of America, about 3 million adults and adolescents tried cannabis for the first time and
about 10% of the population (32 million citizens) have used this drug in 2012 [135]. It is
noteworthy that cannabis consumption is easier in the United States of America as it is more
and more accessible due to its legalization in some state for either therapeutic intervention (20
states in March 2014: Alaska, Arizona, California, Colorado, Connecticut, Delaware, Hawaï,
Maine, Massachusetts, Michigan, Montana, Nevada, New Jersey, New‐Mexico, Oregon, Rhode
Island, Vermont, Virginia, Washington DC, and Washington state) [33, 34, 136] or even more
recently for recreational use (Alaska, Colorado, and Washington state, [137, 138]).
In conclusion, misuse or repeated use of cannabis may lead to societal and health issues.
Cannabis abuse is correlated with poor academic performance, legal problems, risky behav‐
iors, unemployment, road accidents, and a higher risk of developing psychological disor‐
ders, respiratory diseases, and cardiovascular problems [6, 19, 139–141]. In addition, its
consumption is often associated with other psychostimulants to potentiate their effects, which
makes this polyconsumption more dangerous for the individual. For example, alcohol taken
together with cannabis may increase the risk of death car accident of about 15 times [142].
3.2. Cannabis and adolescents
The popularity of cannabis has grown substantially in recent years among young people. In
Europe, a survey performed in 2011 (European School Project on Alcohol and other Drugs)
showed that about 24% of the young population has taken cannabis at least once, 20% in the
year 2011, and 12% within the last month [4, 142]. Similar to patterns of adult use, more boys
are consumers of cannabis (1.5 times more than girls), probably because risk‐taking behavior
is more pronounced in boys. Consumption is recreational for most young users, but about 2%
of them become intensive users. Even though cannabis is still illegal in most places, it is largely
perceived as harmless. Thus, there is a normalization of usage among the young population
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which has spread among many countries and is therefore a growing health concern. Indeed,
the most striking observations related to consumption during adolescence are a predisposi‐
tion to develop psychiatric and cardiovascular pathologies [6, 134]. In the latter case, a recent
study was performed on data collected by the French Addictovigilance Network from 2006
to 2010, a nationwide network of regional addictovigilance centers focused on achieving
reliable surveillance of abuse and pharmacodependence cases. They analyzed spontaneous
reports of cardiovascular complications related to cannabis use and showed some death cases
from coronary syndromes, juvenile arteriopathies, and acute cerebral angiopathy [143].
Association with an increased risk of myocardial infarction has also been reported, with
aggravation of coronary ischemia and even triggering of myocardial infarction [144]. Also,
myocardial infarction, sudden cardiac death, cardiomyopathy, stroke, transient ischemic
attack, and arteritis have been described [136]. Complications can occur in young users without
preexisting cardiovascular problems [136] and at a greater frequency [143]. Therefore, potential
for marijuana‐associated adverse cardiovascular effects is of extreme seriousness as it may
even have been underestimated if the analysis were based on spontaneous reports [143].
Recreational consumption by adolescents may lead to subsequent drug abuse. Cannabis has
been proposed as a gateway drug [145, 146]. This hypothesis is still debated and neurobiolog‐
ical mechanisms are still not fully understood. Preclinical studies suggest nevertheless that
cannabis may facilitate the sampling of other drugs of abuse such as alcohol, cocaine, and
heroin. Indeed, rat exposure to Δ9‐THC during adolescence increases voluntary heroin intake
in adulthood [147]. Furthermore, data analysis of transcriptomic and DNA methylation
modifications has revealed a generational transmission of adaptations both at the neurobio‐
logical and behavioral levels in animals with parental exposure to Δ9‐THC [148, 149]. These
observations suggest long‐term adaptations and germinal transmission which may involve
epigenetic events with gene expression modulations such as DNA methylation or histone post‐
translational modification [150, 151].
Academic difficulties have also been observed among occasional cannabis users during
adolescence [139]. Regular consumption is predictive of a person having a higher risk of
problems with other drugs in adulthood, along with psychological and societal issues [139].
It has been shown that consumption during adolescence may increase chronic psychosis and
this phenomenon is reinforced when there is a genetic predisposition to the problem [19].
3.3. Dependence on cannabis
As opposed to cocaine or heroin, cannabis has often been considered a less harmful drug with
low dependence properties and minimal negative effects, but its addictive potential has long
been questioned [152]. Recent research has made strong progress in the knowledge of the
mechanisms of action of cannabis and no doubt has subsisted that cannabis is an addictive
drug. Moreover, an increasing number of cannabis consumers are seeking efficient treat‐
ments indicating that a growing fraction of the population is being dependent on cannabis.
Chronic consumption of a drug may lead to addiction and this brain disease can be charac‐
terized by specific behavioral consequences: compulsive drug seeking, uncontrolled‐drug
intake, craving for the drug, and strong potential for relapse. This addictive behavior evolves
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despite its adverse consequences on everyday life. This phenomenon has been well docu‐
mented by several reviews which propose a model for this spiral of addiction [62, 153–156]. It
develops in a small proportion of casual users and relies on psychological, genetic and
environmental factors participating to the individual vulnerability [157–160]. To precisely
evaluate this pathological process, the American Psychiatric Association has proposed the
DSM‐V (Diagnostic and Statistical Manual of Mental Disorders) as a reference for diagnos‐
ing addiction as a mental disorder [161]. Several criterions are documented for this evalua‐
tion and allow classifying the severity of the individual addiction depending on the numbers
of criterions identified.
When cannabis plant is taken, Δ9‐THC enters the body through the lungs and circulating blood,
which causes it to quickly reach the brain. When cannabis is eaten (space‐cake for example),
absorption is slower [35]. Δ9‐THC targets the cannabinoid receptors and therefore heavily
activates the endocannabinoid system, which triggers the psychological and physical effects
of the drug. Among the criterion listed for cannabis, the development of tolerance [162] and
withdrawal syndromes caused by the interruption of consumption [152] are well recognized.
Tolerance is characterized by a decrease of the effects following repeated drug consumption
or by a need to increase the amount taken to reach similar effects [163]. Nevertheless, devel‐
opment of tolerance can vary between individuals in terms of physiological responses or
behavior [164]. Withdrawal syndromes appear when the individual is under abstinence
following chronic intake of the drug or when the individual seeks for the same drug or another
one to alleviate these symptoms [15, 163]. Spontaneous withdrawal is observed in humans to
cause increased agitation and excitability, insomnia, anxiety, aggressiveness, depression state,
anorexia, and tremors [13, 152]. Interestingly, the criterion of craving cannabis has been added
for the first time to the DSM‐V.
Specific animal models have been developed to study drug rewarding effects mediated by
specific brain structures in preclinical research. In order to characterize cannabis effects
observed in humans, rodent models using repeated administration of cannabinoid agonists
have been elaborated to evaluate consequences of such a chronic exposure as well as the
addictive power of these cannabinoids [165]. This allowed a better understanding of motiva‐
tional and reinforcing properties of these drugs [15]. The self‐administration paradigm (SA)
is recognized as the most powerful model for measuring both the rewarding and motivation‐
al effects of a drug [166]. It is an operant system based on a voluntary procedure to obtain the
drug, coupled with the association of a signal [167]. Intravenous (iv) SA has been rather difficult
to establish for Δ9‐THC (probably due to its partial agonistic nature) and several adaptations
were necessary to obtain a reliable model. Indeed drug priming, low doses, food restriction,
and animal restraint were useful to measure cannabinoid agonists properties in this task [96,
165, 168]. Both Δ9‐THC and the synthetic cannabinoid WIN55,212‐2 have been successfully
described to promote self‐administration in rats and mice, and extended to the study of mice
deficient for cannabinoid receptors [169–172]. Other synthetic compounds were also success‐
ful, such as CP 55,940 and HU‐210 [173]. Moreover, the selective antagonist of CB1 receptor
(rimonabant or SR141716A) was able to reverse cannabinoid‐induced iv SA, illustrating the
major role of this receptor in reinforcing properties of the drugs [171]. Interestingly, stable iv
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SA of Δ9‐THC was obtained in squirrel monkeys, with much lower doses than for rodent
studies [174, 175], illustrating potential differences in the pharmacodynamic and kinetic
properties of this drug across species.
A task evaluating the conditioned place preference (CPP) has been developed to study
reinforcing properties of drugs associated with an environmental cue like the context in which
the drug is administered [176]. Interestingly, conflicting evidence exist about either positive
(CPP) or negative (CPA) properties of cannabinoids, depending on experimental conditions
used [96]. Agonists such as Δ9‐THC and CP 55,940 used at high doses produce aversion,
therefore animals will avoid the compartment where the drug was injected [177–180]. Also,
the antagonist SR141716A induced CPP at low and high doses in rats, revealing reinforcing
properties [180]. Nevertheless, reinforcing properties can be observed with low doses of Δ9‐
THC, longer conditioning periods or priming injections of the drug in the home cage prior to
conditioning [181]. This nonoperant paradigm with specific experimental conditions has been
used to study cannabinoid effects in genetically modified mice (for review see [182]). Finally,
withdrawal signs following repeated exposure to Δ9‐THC can be measured in rodents. They
may be either spontaneous or precipitated by a selective CB1 antagonist, and somatic signs
can be scored for providing an index of dependence [152, 183]. For example, mice exhibited
several signs including tremor, ataxia, piloerection, ptosis, and decreased motor activity [177,
184].
3.4. Medications for cannabis dependence
Besides preclinical evidence of cannabis‐induced dependence in rodent studies, demand for
treatment of cannabis use disorders is increasing. This illustrates the fact that an increasing
number of people are dependent on cannabis. In the United States of America, more people
are dependent on cannabis than cocaine (4.5 and 1 million in 2010, respectively) and there‐
fore more people are seeking treatment for the first, rather than second, drug [185]. In 2013,
about 845,000 people aged more than 12 years old received treatment because of their cannabis
consumption [5]. In general, adults seeking treatment have been regular users for more than
10 years and have already tried to reduce or stop their behavior [134, 152].
There are currently no approved medications for the treatment of cannabis dependence and
cannabinoid antagonists could be a potential pharmacotherapy [186]. The use of selective CB1
antagonists for the treatment of drug dependence has been investigated in preclinical studies
as CB1 receptors are highly expressed in brain structures related to reward (see Section 2.1)
[187, 188]. In a study using squirrel monkeys, rimonabant, a selective CB1 antagonist with
some inverse agonistic properties, blocked cue‐induced drug seeking, Δ9‐THC‐induced drug
seeking, and the direct reinforcing effects of Δ9‐THC suggesting that this compound may help
to maintain abstinent behavior [189]. Such medications might be effective treatments for
cannabinoid dependence, but they have not been tested on humans’ cannabis reinforcing
effects.
Cognitive behavioral therapy associated with contingency management is quite efficient for
treating cannabis dependence [4, 134]. Moreover, family‐based interventions may help
adolescents dealing with cannabis withdrawal and craving and social help for employment is
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also crucial for limiting relapse [4]. Proposed therapeutic approaches are based on existing
ones known to be effective in the treatment of other drug use disorders like baclofen for
alcoholic withdrawal. Some clinical studies suggest that existing medications for other
indications may be promising target for cannabis use disorder. Among them, buspirone,
bupropion (Zyban®), sodium divalproate (Depakote®), and lithium may have therapeutic
benefits [190]. Bupropion (Zyban®) is an inhibitor of noradrenalin and dopamine recapture,
and an antagonist of nicotinic receptors. It is used to treat nicotinic withdrawal, and is an
antidepressant. Sodium divalproate (Depakote®) is an antiepileptic drug used to treat bipolar
symptoms. Buspirone is used as an anxiolytic and lithium as a thymoregulator. Finally, novel
approaches have focused on cannabinoid replacement therapy (CRT) and showed that
Sativex®(Nabiximols), a buccal spray containing Δ9‐THC and CBD used to treat spasticity
associated with MS, may be a useful substitutive medication for cannabis dependence [40].
Nevertheless, controlled clinical trials are needed to confirm potential therapeutic efficacy of
these molecules in cannabis‐dependent treatment [190].
3.5. Synthetic cannabinoids
A more recent problem that has strongly increased the risks of drug use is the proliferation
worldwide of new derivatives of synthetic cannabinoids. These drugs, also known as synthetic
marijuana, “Spice,” or “K2,” are often less controlled and are being sold on the Internet which
greatly facilitates their access [2, 191, 192]. Spices usually look like a mixture of dry herb plants
where a multitude of compounds have been sprayed. More recently, these molecules have
been sold for liquid preparation used in e‐cigarettes [193]. These synthetic compounds are
analogs of cannabinoids, but the exact content of the mixtures is not fully known and many
chemical types of compounds are now being produced. They induce similar euphoric and
relaxing effects as classical cannabis derivatives but they present a much higher potency. It is
not even clear that they all contain Δ9‐THC [194]. Also, they do not contain CBD, which is
suggested to balance the antipsychotic effects of Δ9‐THC in cannabis [195]. There may be
specific risks associated with these new drugs compared to those known for cannabis. Indeed,
they produce increased or even additional adverse effects, such as tachycardia, hypertension,
chest pain, cardiac palpitation, intense sweating, convulsions, drowsiness, and agitation [192,
193, 196]. In adolescents, hallucinations, paranoia, and myocardial infarction have been
reported [197]. More toxicology studies are needed to better characterize the adverse effects
of these substances [198]. Altogether, synthetic cannabinoids represent a significant public
health issue with an evolving legal market place that specifically target young populations and
is difficult to control.
3.6. Cannabinoid‐opioid interactions
Mechanisms of action are yet more complex as the endocannabinoid system interacts with
other neuromodulatory systems such as the hypocretin, dopaminergic, adenosinergic, and
opioid systems. The latter is of particular interest as the endocannabinoid and the opioid
systems share neuroanatomical, neurochemical, and pharmacological characteristics [199–
202]. The opioid system consists of three GPCR named mu, delta, and kappa receptors which
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interact with endogenous ligands (enkephalins, dynorphins, and endorphins) as well as
exogenous ligands, including morphine or heroin. A hypothesis of cross‐modulation in‐
cludes the release of opioid peptides induced by cannabinoids (or reversely of endocannabi‐
noids by opioids), and possible direct interaction at the level of receptors or signaling
pathways. Evidence for specific interactions in the modulation of nociception has been
provided both with in vitro and in vivo approaches [203, 204]. In the context of responses
associated with reward and relapse, specific mechanisms have been highlighted, in particu‐
lar with the use of knockout approaches [182]. Noticeably the mu opioid receptor has been
proposed as a convergent molecular target mediating rewarding properties of opioid
compounds but also of other drugs of abuse, including cannabinoids [205, 206]. The partici‐
pation of the enkephalinergic system, with a joint action of mu and delta receptors, in
behavioral responses associated with cannabinoid dependence has been clearly demonstrat‐
ed. Moreover, chronic exposure to cannabinoid agonists induced a modification in both the
density of mu opioid receptors and their activity in structures related to reward, which may
contribute to the development of cannabinoid dependence [207]. Interestingly, studies using
cannabinoid iv SA experiments have shown that opioid antagonists can block cannabinoid
intake in mice and rats [169] and in squirrel monkeys [175]. Moreover, iv SA of morphine is
abolished in animals deficient for the CB1 receptor [208], confirming a role for CB1 receptor
in the modulation of opioid reward [182, 209]. Additionally, the antagonist rimonabant can
precipitate withdrawal signs in morphine dependent animals and reciprocally, the opioid
antagonist naloxone can precipitate these effects in cannabinoid dependent rats [210]. Another
cross‐interaction occurs at the cellular levels with colocalization of CB1 and opioid receptors
observed in several brain structures including limbic areas, mid‐brain, brain stem, or spinal
cord [182, 211, 212]. Also, heterodimerization processes between cannabinoid and opioid
receptors have been reported in both in vitro and more recently in vivo, in neuronal popula‐
tions [213, 214]. This physical proximity is suggested mainly for CB1 receptors and delta or
mu receptors and may impact on signaling properties of these receptors in specific brain
structures, therefore possibly influencing analgesic or addictive responses involving these
receptors. More research remains to be done to decipher the physiological role of such
heteromers [214, 215].
4. Therapeutic perspectives
Even though cannabinoids are considered a drug of abuse and can induce dependence, they
are used to treat several pathologies, including drug dependence. As developed earlier in this
chapter, there are several risks associated with cannabis use, including altered short‐term
memory and decision making, increased anxiety and psychosis, and an increased risk of
cardiovascular and lung diseases. On the other hand, the beneficial effects of cannabinoids in
specific pathologies are worth trying to develop for medical use and therefore represent a main
therapeutic challenge for health science. Several therapeutic strategies are currently being
developed with some limitations. Figure 1 and Table 3 summarize some of these approaches.
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Figure 1. Therapeutic interventions targeting the endocannabinoid system. Commercialized compounds or mole‐
cules under study for targeting the endocannabinoid system are acting on different processes. Two main strategies are
being developed to target the endocannabinoid system. A direct process will focus on compounds that bind to the
cannabinoid receptors CB1 and/or CB2 receptors, with full, partial, or inverse agonists or antagonists (see text for de‐
tails). An indirect process will aim at increasing endocannabinoid levels in situ and, therefore, target either the reup‐
take of anandamide and 2‐AG or their degradation by their specific enzymes, FAAH and MAGL, respectively. Only
the presynaptic neuron is represented here. Thin arrows represent the action of endogenous (hatched) or exogenous
(plain) ligands on cannabinoid receptors. For detailed references, see the text. Abbreviations: AEA, anandamide; 2‐AG,
2‐arachidonoylglycerol; AT, anandamide transporter; CB, cannabinoid; FAAH, fatty acid amide hydrolase; MAGL,
monoacylglycerol lipase.
4.1. Cannabidiol as a promising therapeutic medication
Cannabidiol (CBD) is a phytocannabinoid that has a low affinity for both receptors CB1 and
CB2 with inverse agonistic properties [96, 216] and antagonistic effects, with CB2 receptors in
particular [216] (see Section 1). This action explains the opposite effects of CBD toward Δ9‐THC
and illustrates the interest to associate both compounds for developing a new medication. As
mentioned earlier, CBD is commercialized in association with Δ9‐THC as Sativex®. Other
properties such as anxiolytic, antidepressor, and antipsychotic effects have been observed with
CBD [217]. Recent studies have revealed that CBD can decrease the cognitive and memory
impairments induced by Δ9‐THC in male rhesus monkeys [218]. Evidence from several
research domains suggests that CBD can be used for antipsychotic treatment (for reviews,
see [219, 220]). A clinical study shows that anxiety and psychotic effects produced by a high
concentration of Δ9‐THC can be reversed by CBD administration. Animal studies investigat‐
ed the pharmacological profile of this phytocannabinoid and revealed a similar pattern to
atypical antipsychotic drugs (clozapine or risperidone). Also, clinical studies on schizophren‐
ic patients using CBD demonstrated a potential for this drug to be used as an alternative
treatment for schizophrenia [220]. More investigations are still needed to better demonstrate
the potential of this phytocannabinoid as a medication.
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Strategy Therapeutic potential Limitation
Medicinal cannabis
(phytocannabinoid
including:
Δ9‐THC, CBD,
Δ8‐THC, CBN, etc.)
Severe pain (neuropathic, AIDS‐associated,
postsurgery, chronic)
Muscle spasticity; cancer; cachexia, glaucoma,
nausea
Adverse effects (psychosis)
Safety issues (drug interaction
unknown)
Therapeutic benefit not fully
proved
Various pharmacodynamic and
pharmacologic profiles
Difficult dosage regimen
Cannabidiol Anxiety; depression; psychosis(schizophrenia,
bipolar disorders)
Opiate dependence
Pain
Neurodegenerative diseases (AD, PD)
Inflammatory diseases (rheumatoid arthritis)
Brain ischemia
Diabetes; nausea ; cancer
Clinical trials needed
CB2 receptor agonist Chronic inflammatory and neuropathic pain
Neurodegenerative and neuroinflammatory
diseases (AD, MS, HD, ALS, brain ischemia)
Osteoporosis
Peripheric inflammatory disorders
(atherosclerosis, nephropathy, liver disease)
Cocaine dependence
Poor results in clinical trials
compare with preclinical data
CB1 receptor antagonist Drugs of abuse dependence(cannabinoids,
nicotine, alcohol, opiates)
Obesity; metabolic disorders
Adverse effects (anxiety,
depression, suicides)
Clinical trials needed
Peripheric CB1 receptor
antagonist
Weight gain Atherosclerosis
Gastrointestinal, liver, pancreatic or coronary
artery diseases
Arthritis
Preclinical studies to complete
Clinical trials needed
Inhibitors of
endocannabinoids
degradation or
inhibitors of recapture
transporter
Anxiety; depression
Opiate dependence
Clinical trials needed
This table lists examples of strategies targeting directly or indirectly the endocannabinoid system being developed or in
progress for treating several pathologies. Most of trials were perform in preclinical studies. For most of candidate
medications clinical trials must be perform or completed to confirm the efficiency in human and the safety of the various
compounds. For detailed references, see the text.
Table 3. Examples of therapeutic strategies targeting the endocannabinoid system.
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Interestingly, a rodent study using iv SA of heroin has revealed a potential for CBD as a
medication for heroin dependence [221]. Indeed, the authors show in their model that CBD
does not alter the intake of heroin, but specifically impairs the seeking behavior reinstated by
a conditioned stimulus cue. This CBD effect is associated with the normalization of neurobio‐
logical changes observed in this model, noticeably in the CB1 receptor expression in struc‐
tures related to reward like Nucleus Accumbens. In humans, opiate dependence is mostly
treated with substitutive therapy like methadone but this molecule does not affect heroin
craving. Therefore, CBD represents a potential alternative to treat heroin craving and re‐
lapse [221].
CBD has been shown to have analgesic properties. Paclitaxel is an anticancer drug that induces
neuropathic pain. In a rodent model with chemotherapy‐induced neuropathic pain and this
medication, CBD was able to decrease mechanical sensitivity [222]. It had no conditioned
rewarding effects and did not affect conditioned learning and memory. The precise mecha‐
nism of action is still not clear and may partly involve the serotonin system [222]. An interac‐
tion of CBD with CB2 receptor has also been suggested in heterologous system [216]. CBD may
be an efficient treatment to reduce the neuropathic pain induced by chemotherapy without
any of the potential side effects of cannabinoids.
Finally, other pathological situations, such as neurodegenerative diseases (Parkinson and
Alzheimer), cerebral ischemia, diabetes, nausea, rheumatoid arthritis, or other inflammatory
problems could be treated with CBD [223, 224]. Additionally, the potential for CBD as a medical
intervention in psychotic disorder has been reviewed recently [219]. CBD represents a
therapeutic approach for several disorders, but more clinical studies are needed. Also, plants
with higher content in CBD or a low ratio Δ9‐THC/CBD are being produced for medical
application and may not be of interest for euphoric purposes.
4.2. CB2 receptors as targets for medication
Pharmacology has provided many synthetic cannabinoid ligands that specifically interact with
cannabinoid receptors and therefore represent great tools for research and clinical applica‐
tions. The limitation for the use of these compounds as therapeutic drugs so far is that most of
them target CB1 receptors and therefore may lead to adverse psychotic effects [225]. Indeed,
CB1 receptor activation induces most of the central and psychotic effects of cannabis (see
Section 2.1). Even though CB2 receptors are expressed in the CNS (see Section 2.1), they are
mostly involved in inflammatory processes and are therefore less implicated in adverse central
effects. Noteworthy activation of CB2 is not associated with tolerance or withdrawal syn‐
drome in animal models of neuropathic pain [226]. In addition, no CPP or CPA could be
measured using the CB2 agonist JWH‐133 at the doses tested in mice, neither SA with this same
agonist in mice able to self‐administer cocaine, revealing no direct role of the CB2 receptor
associated with reinforcing properties of cannabinoids [127]. Targeting these receptors for
therapeutic purposes is therefore of strong interest [93].
As CB2 is highly expressed in immune cells, a potential role in treating several diseases
including inflammation, cancer, osteoporosis, and liver diseases has been proposed (for a
recent review, see [227]). Thus, CB2 agonists represent promising medication strategies in
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several therapeutic applications with modulation of inflammatory processes without trigger‐
ing psychotic effect [228, 229]. For example, selective activation of CB2 receptors by the
synthetic cannabinoid JWH‐015 suppresses CD40 expression in a model of cultured micro‐
glial cells activated by IFN‐gamma, suggesting a beneficial role of CB2 activation in patho‐
logical activation of microglial cells [230]. This effect may be of interest in the context of
neurodegenerative and neuroinflammatory diseases such as Alzheimer disease (AD), MS, or
Huntington's disease [230–233]. Interestingly, another selective agonist of CB2, AM1241, was
effective at slowing signs of disease progression in an amyotrophic lateral sclerosis (ALS)
mouse model (G93A‐SOD1 transgenic mice) when administered at the onset of tremor signs
[234]. Daily injections of this CB2 agonist also increased the survival interval after disease onset
by 56%, with reduction of motor neuron degeneration and preservation of motor function.
Interestingly, a strong increase of CB2 mRNA expression is observed in the spinal cord of this
mouse model [235]. These observations highlight the therapeutic potential of CB2 agonists for
the treatment of these chronic pathologies.
A study using genetically modified mice deficient for CB2 receptors has revealed a low bone
mass phenotype, suggesting that endocannabinoids play an essential role in the mainte‐
nance of bone mass by signaling through CB2. The authors showed that CB2 receptors are
expressed in cells of both the osteoblast and osteoclast lineages and that exposure of these cells
to a CB2‐specific agonist (HU‐308) results in direct stimulation of osteoblasts and inhibition of
osteoclasts, suggesting that CB2 signaling contributes to the maintenance of normal bone
mass [236]. Thus CB2 selective agonists could play a protector role in osteoporosis and
represent a treatment strategy. In addition, selective agonists for CB2 receptors have been
proposed for the treatment of inflammatory disorders in periphery, including atherosclero‐
sis [237], nephropathy [238] or chronic liver disease [239].
Finally, CB2 receptor expression has been detected in neurons and a modulator role of this
receptor has been proposed in drug addiction (see Section 2.4). Chronic administration of
JWH‐133 CB2 agonist inhibits iv SA of cocaine, cocaine‐induced hyperlocomotion, and
cocaine‐induced levels of dopamine in the Nucleus Accumbens, in wild‐type and mice
deficient for CB1 receptors, but not in knockout mice for CB2 [127]. A similar effect is observed
in the ventral tegmental area with inhibition of dopaminergic activity both in vivo and in vitro
[66]. Therefore, the development of CB2 agonists for the treatment of cocaine dependence may
be a future strategy.
In conclusion, preclinical studies are encouraging for CB2 agonist use in therapeutic ap‐
proaches, but clinical results are rather poor and more studies are still needed. These limited
results may be due to low in vivo selectivity of the tested compounds (which may also interact
with CB1 receptors), individual (gender, age) or interspecies differences in CB2 receptors and
associated signaling pathways [93].
4.3. Cannabinoid antagonists to treat several disorders
Other therapeutic strategies have explored the use of specific antagonists to block cannabi‐
noid effects [188]. Rimonabant was the first CB1 antagonist introduced into clinical practice
[240]. In 2006 in Europe, it was initially developed as a medication (Acomplia®) to treat obesity
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disorders and associated risks such as dyslipidemia, diabetes, and metabolic syndromes [241–
243]. The anorexigenic properties of rimonabant were also encouraging to evaluate the
potential of this compound to avoid weight gain when stopping nicotine consumption. A
random double‐blind clinical study has revealed that the addition of a nicotinic patch with
rimonabant was more efficient than a placebo patch associated with rimonabant to pro‐
longed abstinence following 6–9 weeks of treatment, but weight gain was similar in both
groups [244]. Besides promising effects of this compound, it was withdrawn from the market
in 2008 as strong psychiatric adverse effects have been observed during clinical trials
(increased anxiety, deep depression, and suicide) [38, 240, 245] and was therefore not author‐
ized by the Food and Drug Administration in the United States of America.
Knowing the adverse effects of rimonabant in human, development of any new selective
cannabinoid antagonists with different pharmacodynamics properties (more neutral antago‐
nist) that would possess the same activity both in animals and humans is greatly needed. In
addition, such compound would have to yield a positive benefit/risk ratio to be considered for
a therapeutic use and be tested in clinical research under strictly controlled circumstances that
maximize safety [240]. Alternative perspectives for specific medical conditions are oriented
toward cannabinoid antagonists that will only act on the periphery without CNS related
adverse effects. Such compounds are being developed to treat pain (see [246]) and may also
be useful for obesity and metabolic disorder, as preclinical studies have demonstrated
decreased food intake using LH‐21, an antagonist with a poor penetration rate into the central
nervous system [247]. Likewise, peripheral antagonism may be beneficial for other patholo‐
gies with noticeable peripheral pathophysiologic mechanisms including gastrointestinal, liver,
pancreatic, or coronary artery diseases ([240] and references therein).
Cannabinoid antagonists have also been evaluated for their potential in opiate‐dependence
therapy. Indeed, bidirectional interactions between cannabinoid and opioid systems on
reward processes revealed by both pharmacological and genetic approaches (see Section 3.6)
suggest a possible therapeutic intervention with cannabinoid antagonist for opiate depend‐
ence. For example, rimonabant administration suppresses morphine‐induced CPP and
morphine SA in mice, and heroin SA in rats [173], with the latter effect appearing only in opiate‐
dependent rats but not in nondependent animals [248]. Another therapeutic use for cannabi‐
noid antagonists would be for treatment of nicotine abuse. Preclinical studies have revealed
that CB1 selective antagonists, including rimonabant and AM251, reduced nicotinic SA, as well
as nicotinic‐induced CPP behaviors (see [249]). Besides, clinical studies have shown that
rimonabant was efficient for tobacco smoking cessation, but the therapeutic effects were not
better than other substitutive medications and results for abstinence were not fully convinc‐
ing [250].
Moreover, CB1 antagonists have been evaluated for their use in alcohol dependence (recent‐
ly reviewed in [251]). In preclinical studies, evidence accumulates for the good efficiency of
cannabinoid antagonists to significantly reduce alcohol consumption and attenuate alcohol
withdrawal symptoms. For example, a preclinical study demonstrated that rimonabant may
be effective in reduction of alcohol consumption, most probably by indirect modulation of
dopaminergic transmission [252]. On the other hand, results obtained in animals do not
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necessary translate to human studies. Indeed, a double blind clinical trial with placebo has
been conducted to examine the effect of a 12‐week rimonabant treatment on alcohol‐depend‐
ent patients under detoxification and only a mild effect was observed for efficiency against
relapse [253]. Globally, results on cannabinoid efficiency for alcohol dependence are highly
inconsistent and more clinical studies are needed to confirm an effect in human for this major
health concern worldwide.
4.4. Inhibition of endocannabinoid degradation as a therapeutic strategy
An indirect strategy that is currently developed to target the endocannabinoid system is to
limit the endocannabinoid degradation in order to increase their natural concentration in situ
and amplify their effects. The most targeted enzyme is the FAAH enzyme (see Section 2.2)
which hydrolyses AEA and therefore, by developing potent and selective inhibitors AEA
actions may be prolonged. For example, the URB597 is a selective inhibitor of this enzyme [254,
255]. In both rats and mice it elicits antidepressive and antianxiolytic like effects, likely via CB1
receptor mediated modulation of serotonin and norepinephrine neurotransmission [255–258].
These observations highlight FAAH as an interesting pharmacological target to directly
modulate endocannabinoid levels in the brain and therefore offer a potential treatment for
depression and anxiety phenotype.
In addition, several preclinical studies have shown that the inhibitors of catabolic enzymes
(FAAH and MAGL) may be useful against opiate abuse. Indeed, URB597 protects against
tolerance and memory deficits in chronic morphine treatment and does not interfere with drug‐
induced reinstatement of either conditioned floor preference or avoidance [259]. Moreover,
these inhibitors reduce somatic morphine withdrawal signs but not aversive aspects (CPA
paradigm) [260]. The MAGL inhibitor JZL184 attenuates spontaneous withdrawal signs in
morphine dependent mice. Morphine‐dependent mice challenged with the opiate antagonist,
naloxone, display a profound withdrawal syndrome. In these conditions, both PF‐3845
(FAAH inhibitor) and JZL184 reduce these withdrawal signs, a process that is reversed by a
CB1 antagonist SR141716A [261]. Interestingly, the FAAH inhibitors do not show any adverse
effects such as hypothermia, hypomotility, or catalepsia [81, 262]. In addition, they do not show
reinforcing properties and therefore are a promising therapeutic strategy to treat opiate
dependence with the minimal risk of abuse that is classically observed with cannabinoid
agonists [257, 260]. Interestingly, other authors have evaluated the effects of structurally
different FAAH inhibitors in an animal model of working memory known to be sensitive to
impairment by Δ9‐THC and showed that one FAAH inhibitor (AM3506) decreased accuracy
in the memory task via a CB1‐dependent mechanism, whereas the others had no effect [263].
Another target for increasing endogenous levels of the cannabinoid‐receptor agonist would
be to block the AEA transporter. The endocannabinoid uptake inhibitor AM404 can have
antidepressant effects in the forced swim test in rat (decreased immobility), suggesting a
potential therapeutic effect as for the FAAH inhibitors [264]. On the other hand, a very recent
study demonstrated that AM404 was able to effectively reinforce SA behavior and induce
reinstatement of drug‐seeking behavior in abstinent squirrel monkeys, indicating that such a
compound that promotes increased endocannabinoids may have a potential for abuse [265].
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All these indirect strategies are of particular interest as they amplify cannabinoid receptor
activation specifically where the endocannabinoids are produced, therefore increase signal‐
ing in defined brain structures [255]. Nevertheless, clinical studies are needed to confirm the
therapeutic potential of these molecules in human and it will be crucial to evaluate the effects
of such inhibitors with respect to their potential for memory impairment, abuse liability, and
probably other cannabis‐like effects in clinical trials before any specific therapeutic application.
5. Conclusion
The growing consumption of cannabis and its derivatives in the population and particularly
in the adolescent population represents a real public health challenge. A growing interest has
been developed in cannabis and related compounds in research. Furthermore, considerable
debates involving its legalization are still being conducted and this may have political
consequences. Risk should not be neglected and it seems crucial to widely disseminate more
scientific knowledge about this family of compounds before legalization becomes a normali‐
zation. Cannabis exposure produces a range of behavioral and neurobiological adaptations
and the general public should be more aware of the clinical implications of the long‐term
impact of this drug. Among adaptations, long‐term exposure to drugs of abuse or specific
exposure during a critical period of development may elicit gene expression changes through
epigenetic mechanisms. Recent research using genomic technology has investigated plastici‐
ty mechanisms taking place in brain structures involved in reward circuitry and highlighted
epigenetic control of gene transcription (see Section 3.2). An expected increase of scientific data
in this field will help clarify the molecular mechanisms of drug abuse vulnerability. This
research will also be a new avenue for proposing novel therapeutic interventions for long‐term
cannabis exposure or spreading abuse of synthetic cannabinoids.
Cannabinoid derivatives have positive effects on several other pathologies besides drug
dependence. These applications need further rigorous clinical trials to ensure efficiency and
safety in human and additional cannabinoid‐related compounds need to be developed. In
conjunction, a combination of strategies may be foreseen, as this is the case in other pharma‐
cological fields, with specific care to the dose and duration of treatments. Inventive therapeu‐
tic approaches for treating pain or dependence may also consider targeting heterodimers of
cannabinoid and opioid receptors using antibodies or bivalent ligands or indirectly acting on
both systems using dual enkephalinase and cannabinoid catabolic enzyme inhibitors [266,
267]. Intensive research is now oriented toward such perspectives.
To conclude, and as for the opiate compounds that are used as medication, in particular, to
treat pain (e.g., morphine) or abused for euphoric effects (e.g., heroin), cannabinoids by
targeting a complex endogenous system also constitute a powerful pharmacological tool with
both drug and medication properties. Therefore, future investigations are necessary in order
to propose optimal therapeutic approaches for managing complex diseases and promising
strategies for reducing dependence. The ultimate goal is to propose innovative strategies to
current treatments with increased safety usage.
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